Published in J Physiol on October 25, 2007
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci (2009) 2.19
The Concise Guide to PHARMACOLOGY 2013/14: ligand-gated ion channels. Br J Pharmacol (2013) 1.88
Control of assembly and function of glutamate receptors by the amino-terminal domain. Mol Pharmacol (2010) 1.54
Kinetic basis of partial agonism at NMDA receptors. Nat Neurosci (2009) 1.45
A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat Commun (2010) 1.38
Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat Commun (2011) 1.26
Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders. J Physiol (2012) 1.19
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci (2010) 1.18
Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors. Mol Pharmacol (2013) 1.15
Constitutive activation of the N-methyl-D-aspartate receptor via cleft-spanning disulfide bonds. J Biol Chem (2008) 1.10
Influence of GluN2 subunit identity on NMDA receptor function. Neuropharmacology (2013) 1.07
Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.07
Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int (2012) 1.02
TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology (2012) 0.96
Molecular pharmacology of human NMDA receptors. Neurochem Int (2011) 0.96
Molecular bases of NMDA receptor subtype-dependent properties. J Physiol (2014) 0.91
Agonist-specific gating of NMDA receptors. Channels (Austin) (2010) 0.91
Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator. Mol Pharmacol (2014) 0.89
Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. Br J Pharmacol (2012) 0.89
Structural dynamics of the glycine-binding domain of the N-methyl-D-aspartate receptor. J Biol Chem (2014) 0.88
Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors. J Med Chem (2013) 0.86
Structural mechanism of N-methyl-D-aspartate receptor type 1 partial agonism. PLoS One (2012) 0.85
Identity of the NMDA receptor coagonist is synapse specific and developmentally regulated in the hippocampus. Proc Natl Acad Sci U S A (2014) 0.82
A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance. Front Pharmacol (2014) 0.82
The selectivity of conantokin-G for ion channel inhibition of NR2B subunit-containing NMDA receptors is regulated by amino acid residues in the S2 region of NR2B. Neuropharmacology (2009) 0.81
Pharmacological characterization of recombinant NR1/NR2A NMDA receptors with truncated and deleted carboxy termini expressed in Xenopus laevis oocytes. Br J Pharmacol (2009) 0.80
Glycine-dependent activation of NMDA receptors. J Gen Physiol (2015) 0.78
Activation of EphA receptors mediates the recruitment of the adaptor protein Slap, contributing to the downregulation of N-methyl-D-aspartate receptors. Mol Cell Biol (2013) 0.77
Differential regulation of NMDA receptors by d-serine and glycine in mammalian spinal locomotor networks. J Neurophysiol (2017) 0.75
Disruption of S2-M4 linker coupling reveals novel subunit-specific contributions to N-methyl-d-aspartate receptor function and ethanol sensitivity. Neuropharmacology (2015) 0.75
Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue. Sci Rep (2017) 0.75
Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials. J Biomed Sci (2017) 0.75
Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits. Proc Natl Acad Sci U S A (2017) 0.75
Subtype-specific agonists for NMDA receptor glycine binding sites. ACS Chem Neurosci (2017) 0.75
Identification of AICP as a GluN2C-selective NMDA receptor superagonist at the GluN1 glycine site. Mol Pharmacol (2017) 0.75
VMD: visual molecular dynamics. J Mol Graph (1996) 117.02
Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90
The glutamate receptor ion channels. Pharmacol Rev (1999) 15.06
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 11.44
Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 8.89
NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol (2001) 6.96
Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science (1992) 6.49
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol (1998) 5.93
Subunit arrangement and function in NMDA receptors. Nature (2005) 5.21
Structural basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci (2003) 4.55
Molecular diversity of the NMDA receptor channel. Nature (1992) 3.76
Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J Neurophysiol (1998) 3.67
Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science (1988) 3.54
Glutamate receptors at atomic resolution. Nature (2006) 3.26
Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J (2003) 3.15
Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol (2005) 2.90
Crystal structures of the GluR5 and GluR6 ligand binding cores: molecular mechanisms underlying kainate receptor selectivity. Neuron (2005) 2.65
Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron (1997) 2.54
Activation of NR1/NR2B NMDA receptors. Nat Neurosci (2003) 2.47
Glutamate receptor gating. Crit Rev Neurobiol (2004) 2.31
Modal gating of NMDA receptors and the shape of their synaptic response. Nat Neurosci (2003) 2.26
Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors. J Physiol (1998) 2.26
Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron (1994) 2.11
Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron (2005) 2.07
Zinc potentiates agonist-induced currents at certain splice variants of the NMDA receptor. Neuron (1993) 1.93
Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science (1995) 1.90
Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci (1998) 1.86
Astrocytic control of synaptic NMDA receptors. J Physiol (2007) 1.85
Modulation of N-methyl-D-aspartic acid receptor desensitization by glycine in mouse cultured hippocampal neurones. J Physiol (1990) 1.77
A kinetic analysis of the modulation of N-methyl-D-aspartic acid receptors by glycine in mouse cultured hippocampal neurones. J Physiol (1990) 1.76
Maximum likelihood fitting of single channel NMDA activity with a mechanism composed of independent dimers of subunits. J Physiol (2005) 1.74
Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A (1998) 1.71
AMPA receptor binding cleft mutations that alter affinity, efficacy, and recovery from desensitization. J Neurosci (2005) 1.70
Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine. Biophys J (1991) 1.66
Single-channel currents from recombinant NMDA NR1a/NR2D receptors expressed in Xenopus oocytes. Proc Biol Sci (1996) 1.65
Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol (2007) 1.56
Structure of the kainate receptor subunit GluR6 agonist-binding domain complexed with domoic acid. Proc Natl Acad Sci U S A (2005) 1.48
Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA. J Neurosci (1994) 1.45
Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol (2004) 1.45
Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol (1998) 1.35
Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33
Taking the time to study competitive antagonism. Br J Pharmacol (2007) 1.33
Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci (1998) 1.32
Interdomain interactions in AMPA and kainate receptors regulate affinity for glutamate. J Neurosci (2006) 1.30
Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. Br J Pharmacol (2006) 1.29
Interactions between the glycine and glutamate binding sites of the NMDA receptor. J Neurosci (1993) 1.27
Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature (1989) 1.25
Cloning and expression of the epsilon 4 subunit of the NMDA receptor channel. FEBS Lett (1992) 1.23
Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci (1997) 1.21
Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20
Intersubunit cooperativity in the NMDA receptor. Neuron (2001) 1.19
Activation of N-methyl-D-aspartate receptors by glycine: role of an aspartate residue in the M3-M4 loop of the NR1 subunit. Mol Pharmacol (1996) 1.12
Single-channel analysis of a point mutation of a conserved serine residue in the S2 ligand-binding domain of the NR2A NMDA receptor subunit. J Physiol (2006) 1.09
Mg2+ and memantine block of rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes. J Physiol (2007) 1.07
Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket. J Pharmacol Exp Ther (2005) 1.03
Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site. Mol Pharmacol (1995) 1.00
Tweaking agonist efficacy at N-methyl-D-aspartate receptors by site-directed mutagenesis. Mol Pharmacol (2005) 0.98
Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site. Mol Pharmacol (1990) 0.98
Equilibrium and kinetic study of glycine action on the N-methyl-D-aspartate receptor in cultured mouse brain neurons. J Physiol (1992) 0.96
Single-channel analysis of an NMDA receptor possessing a mutation in the region of the glutamate binding site. J Physiol (2000) 0.92
Disruption of interdomain interactions in the glutamate binding pocket affects differentially agonist affinity and efficacy of N-methyl-D-aspartate receptor activation. J Biol Chem (2006) 0.92
Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex. Mol Pharmacol (1994) 0.91
Effects of (+)-HA-966 and 7-chlorokynurenic acid on the kinetics of N-methyl-D-aspartate receptor agonist responses in rat cultured cortical neurons. Mol Pharmacol (1991) 0.85
Influence of a threonine residue in the S2 ligand binding domain in determining agonist potency and deactivation rate of recombinant NR1a/NR2D NMDA receptors. J Physiol (2004) 0.85
5,7-Dichlorokynurenic acid, a potent and selective competitive antagonist of the glycine site on NMDA receptors. Neurosci Lett (1990) 0.83
Glutamate receptors: variation in structure-function coupling. Trends Pharmacol Sci (2006) 0.78
Glutamate unbinding reveals new insights into NMDA receptor activation. J Physiol (2006) 0.76
Structural basis for partial agonist action at ionotropic glutamate receptors. Nat Neurosci (2003) 4.55
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci (2008) 4.04
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res (2003) 3.47
Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles. J Physiol (2005) 2.90
Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294. Nat Struct Mol Biol (2009) 2.50
Activation of NR1/NR2B NMDA receptors. Nat Neurosci (2003) 2.47
Channel-mediated tonic GABA release from glia. Science (2010) 2.42
Cerebral glucose metabolism in obsessive-compulsive hoarding. Am J Psychiatry (2004) 2.40
Mechanism of Ca2+/calmodulin-dependent kinase II regulation of AMPA receptor gating. Nat Neurosci (2011) 2.31
Glutamate receptor gating. Crit Rev Neurobiol (2004) 2.31
Control of NMDA receptor function by the NR2 subunit amino-terminal domain. J Neurosci (2009) 2.19
The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science (2004) 2.18
Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A (2012) 2.14
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem (2004) 2.09
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther (2003) 2.07
The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron (2012) 1.97
Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol Pharmacol (2003) 1.91
Astrocytic control of synaptic NMDA receptors. J Physiol (2007) 1.85
Functional interaction between paramyxovirus fusion and attachment proteins. J Biol Chem (2008) 1.78
Modulation of the dimer interface at ionotropic glutamate-like receptor delta2 by D-serine and extracellular calcium. J Neurosci (2009) 1.63
TREK-1 and Best1 channels mediate fast and slow glutamate release in astrocytes upon GPCR activation. Cell (2012) 1.60
Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chem Biol (2012) 1.60
Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci (2008) 1.58
Activation of recombinant NR1/NR2C NMDA receptors. J Physiol (2008) 1.57
Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors. Mol Pharmacol (2007) 1.56
Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci (2009) 1.56
Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol (2003) 1.55
Control of assembly and function of glutamate receptors by the amino-terminal domain. Mol Pharmacol (2010) 1.54
Neuroligin-1 is required for normal expression of LTP and associative fear memory in the amygdala of adult animals. Proc Natl Acad Sci U S A (2008) 1.54
The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol (2003) 1.52
Probing the spatial organization of measles virus fusion complexes. J Virol (2009) 1.50
EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs (2005) 1.48
P2Y1 receptor signaling is controlled by interaction with the PDZ scaffold NHERF-2. Proc Natl Acad Sci U S A (2005) 1.48
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42
Excitatory actions of GABA in the suprachiasmatic nucleus. J Neurosci (2008) 1.41
Homeostasis of intrinsic excitability in hippocampal neurones: dynamics and mechanism of the response to chronic depolarization. J Physiol (2009) 1.41
The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A (2003) 1.40
Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci (2010) 1.39
A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. Nat Commun (2010) 1.38
Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol (2008) 1.38
Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases. J Mol Biol (2010) 1.37
The bioactive Taxol conformation on beta-tubulin: experimental evidence from highly active constrained analogs. Proc Natl Acad Sci U S A (2004) 1.37
Ionotropic glutamate-like receptor delta2 binds D-serine and glycine. Proc Natl Acad Sci U S A (2007) 1.36
Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. Exp Neurol (2004) 1.36
Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement (2010) 1.35
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation. J Am Chem Soc (2007) 1.34
Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol (2007) 1.34
Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol (2004) 1.34
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther (2006) 1.33
Mechanism of partial agonism at NMDA receptors for a conformationally restricted glutamate analog. J Neurosci (2005) 1.33
Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One (2011) 1.32
New advances in NMDA receptor pharmacology. Trends Pharmacol Sci (2011) 1.32
A computational neurodegenerative disease progression score: method and results with the Alzheimer's disease Neuroimaging Initiative cohort. Neuroimage (2012) 1.31
Structural aspects of AMPA receptor activation, desensitization and deactivation. Curr Opin Neurobiol (2007) 1.30
Mitochondrial calcium uniporter Mcu controls excitotoxicity and is transcriptionally repressed by neuroprotective nuclear calcium signals. Nat Commun (2013) 1.30
Pharmacological insights obtained from structure-function studies of ionotropic glutamate receptors. Br J Pharmacol (2006) 1.29
Highly active anticancer curcumin analogues. Adv Exp Med Biol (2007) 1.27
Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem (2005) 1.27
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors. Nat Commun (2011) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Activin/Nodal inhibition alone accelerates highly efficient neural conversion from human embryonic stem cells and imposes a caudal positional identity. PLoS One (2009) 1.24
Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother (2007) 1.24
Blind prediction of host-guest binding affinities: a new SAMPL3 challenge. J Comput Aided Mol Des (2012) 1.23
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle (2008) 1.23
Bestrophin-1 encodes for the Ca2+-activated anion channel in hippocampal astrocytes. J Neurosci (2009) 1.22
Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci (2012) 1.22
Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J Neurosci (2005) 1.21
Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J Neurosci (2005) 1.21
Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. J Med Chem (2010) 1.20
Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol Pharmacol (2005) 1.20
Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci (2003) 1.20
Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci (2010) 1.19
Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors. J Physiol (2009) 1.19
Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci (2010) 1.18